Osivax combines its T-cell technology with antibody-based vaccines to develop a next generation of vaccines empowering both arms of the immune system.

Find the Osivax style guide with brand assets such as logos, colors, fonts, and more.

Osivax is a clinical-stage biotechnology company developing a transformative pipeline of universal vaccines uniquely designed to leverage both arms of the immune system: superior T-cell …

Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM, to develop transformative, first-in-class pan …

2025年3月4日 · Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced the …

The company's vaccine leverages its technology and acts as a universal vaccine against all existing and emerging coronavirus infections, preventing globally impactful infectious …

2017年6月23日 · Mission: Osivax was formed as a spin-off of Imaxio’s R&D department and develops a number of clinical and preclinical vaccine candidates based on its OligoDOM …

2025年3月4日 · Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM TM, to develop transformative, first-in …

2025年3月7日 · Osivax S.A.S. - BioCentury Company Profiles for the biopharma industry

Please refine your search by (Localization + What, who? ... Edit search Login / Register My account